Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Excelsior Medical Co., Ltd. (4104.TW)
New Taipei City, TW
Excelsior Medical Co., Ltd. operates as a distributor of a diverse range of healthcare technology and products throughout various Asian nations, specifically Taiwan, mainland China, Japan, South Korea, Malaysia, and the Philippines. Its extensive portfolio encompasses specialized machinery for hemodialysis, routine pharmaceuticals for healthcare facilities, surgical instrumentation, and electronic aids for medical professionals, in addition to cosmetic devices. The company further extends its services to offer administrative support tailored for individual medical departments. Established in 1988, Excelsior Medical maintains its headquarters in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.86% | -1.99% | -11.41% | -11.97% | -17.54% | -13.89% | -16.31% | -12.58% | +47.62% | +73.66% | +40.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-07 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+2.9% Q1'26: +9.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+3.0% Q1'26: -1.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-17.9% Q1'26: +9.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.4% ★ Q1'26: +7.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+5.8% ★ Q1'26: +5.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+21.3% Q1'26: +22.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.07× ★ Q1'26: 2.99× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.20B
est: 6.14B (+1.1%)
|
6.21B
est: 6.14B (+1.1%)
|
6.10B
est: 6.32B (-3.5%)
|
6.46B
est: 6.53B (-1.1%)
|
6.68B
est: 6.99B (-4.5%)
|
7.19B
est: 6.86B (+4.8%)
|
8.23B
est: 7.90B (+4.2%)
|
8.54B
est: 8.74B (-2.3%)
|
8.79B
est: 8.91B (-1.4%)
|
| EBITDA |
707.82M
est: 906.88M (-21.9%)
|
474.99M
est: 906.88M (-47.6%)
|
563.26M
est: 933.03M (-39.6%)
|
624.28M
est: 964.65M (-35.3%)
|
1.01B
est: 1.03B (-2.2%)
|
1.20B
est: 1.01B (+18.1%)
|
968.56M
est: 1.17B (-17.1%)
|
1.18B
est: 1.23B (-4.5%)
|
1.04B
est: 1.26B (-17.2%)
|
| EBIT |
582.43M
est: 717.32M (-18.8%)
|
379.50M
est: 717.32M (-47.1%)
|
452.56M
est: 738.00M (-38.7%)
|
464.04M
est: 763.01M (-39.2%)
|
840.15M
est: 816.89M (+2.8%)
|
974.15M
est: 801.70M (+21.5%)
|
702.88M
est: 923.70M (-23.9%)
|
878.29M
est: 948.00M (-7.4%)
|
739.84M
est: 966.22M (-23.4%)
|
| Net Income |
379.00M
est: 395.52M (-4.2%)
|
389.56M
est: 395.52M (-1.5%)
|
399.05M
est: 471.90M (-15.4%)
|
514.76M
est: 574.12M (-10.3%)
|
571.67M
est: 631.54M (-9.5%)
|
667.45M
est: 610.80M (+9.3%)
|
746.61M
est: 705.32M (+5.9%)
|
771.26M
est: 935.46M (-17.6%)
|
805.86M
est: 995.92M (-19.1%)
|
| SGA |
883.71M
est: 732.41M (+20.7%)
|
817.22M
est: 732.41M (+11.6%)
|
753.74M
est: 753.53M (+0.0%)
|
767.95M
est: 779.06M (-1.4%)
|
774.52M
est: 834.07M (-7.1%)
|
893.28M
est: 818.56M (+9.1%)
|
973.59M
est: 943.13M (+3.2%)
|
1.03B
est: 1.07B (-3.5%)
|
1.15B
est: 1.09B (+5.5%)
|
| EPS |
2.93
est: 2.30 (+27.7%)
|
2.77
est: 2.30 (+20.7%)
|
2.80
est: 2.74 (+2.2%)
|
3.47
est: 3.33 (+4.0%)
|
3.51
est: 3.67 (-4.2%)
|
4.08
est: 3.55 (+15.2%)
|
4.57
est: 4.09 (+11.6%)
|
4.48
est: 4.48 (+0.1%)
|
4.62
est: 4.77 (-3.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 144.8K | 0.65% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 20.4K | 0.42% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 39.6K | 0.44% |
| 4 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 13.6K | 0.33% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 117.2K | 0.46% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 357.9K | 0.39% |
| 7 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 12.4K | 0.56% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 177.8K | 0.29% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 202.4K | 0.28% |
| 10 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 218.5K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng-Hsiao Chou | Chief Financial Officer, Accounting Chief & Corporate Governance Officer | — | male |
| Ming-Cheng Chang | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4104.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
